Physician profile
Min Liang
NPI 1295053684
$3,860.73
in general payments reported to CMS, 2019-2025
21 companies · $16.35 in 2025
The $16.35 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,110 · 2020: $1,276 · 2021: $751 · 2022: $312 · 2023: $126 · 2024: $270 · 2025: $16.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $411.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $508.92 | 2019-2025 | Repatha |
| Abbott Laboratories | $508.85 | 2019-2024 | Jot Dx, Assurity, Freestyle Libre 3 |
| Novo Nordisk INC | $384.89 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $319.34 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $293.48 | 2019-2021 | |
| Boston Scientific Corporation | $288.51 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $241.20 | 2019-2022 | |
| Amarin Pharma, INC. | $214.81 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $198.10 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $147.47 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $133.57 | 2019-2021 | |
| Gilead Sciences, INC. | $127.08 | 2024 | Vemlidy |
| Abiomed | $113.47 | 2022 | |
| Lilly USA, LLC | $78.56 | 2020-2021 | |
| Esperion Therapeutics, INC. | $73.81 | 2020-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.48 | 2019 | |
| Shockwave Medical, INC | $49.06 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Kowa Pharmaceuticals America, INC. | $41.82 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $34.50 | 2019 | |
| Organon LLC | $27.05 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Min Liang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.